Alzheimer-kór: vizsgálatok itt: Japán
21 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
- Where
- Bunkyo-ku, Fukuoka, Hadano, Kanzaki-Gun Yoshinogari-Cho, Karatsu-shi, Kawasaki, Okayama, Sakai, Shimotsuke-shi, Tochigi
- Életkor
- 55 év to 90 év
- People
- 426 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07011732 · EU 2025-520613-31-00 - 3. fázisTaking peopleA Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
- Where
- Aichi, Hyōgo, Tokyo
- Életkor
- 55 év to 80 év
- People
- 1600 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07717411 - 1. fázisTaking peopleA Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease
- Where
- Bunkyō City, Ōbu
- Életkor
- 18 év to 85 év
- People
- 179 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07787169 - 2. fázisTaking peopleA Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
- Where
- Bunkyō City, Fujisawa, Himeji, Inage, Kawasaki, Kobe, Kōtoku, Kurashiki, Nagoya, Ōbu, Suita, tabashi City, Tachikawa, Toride, Yokohama, Yufu
- Életkor
- 55 év to 85 év
- People
- 350 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07589595 - 1. fázisTaking peopleA First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
- Where
- Bunkyō City
- Életkor
- 50 év to 85 év
- People
- 56 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06297590 · EU 2024-510604-37-00 - 3. fázisTaking peopleA Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
- Where
- Chūōku, Hachiōji, Ōbu, Shinjuku, Shinjyuku, tabashi City
- Életkor
- 55 év and over
- People
- 550 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07602582 - 3. fázisTaking peopleA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
- Where
- Fukuoka, Hachiōji, Hadano, Himeji-Shi, Hiroshima, Iizuka, Kanzaki-Gun Yoshinogari-Cho, Kawasaki-Shi, Kōriyama, Kumamoto, Kyoto, Sakai, Sapporo, Setagaya-Ku, Takamatsu, Takatsuki, Tatebayashi, Toride-shi, Tsu, Wako-Shi, Yokohama, Yoshinogawa
- Életkor
- 55 év to 90 év
- People
- 406 worldwide
- Run by
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT06585787 · EU 2024-516363-92-00 - 1. fázisTaking peopleA Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease
- Where
- Bunkyō City, Ōbu
- Életkor
- 18 év to 85 év
- People
- 68 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07787182 · EU 2026-527295-81-00 - No phaseTaking peopleREXULTI General Use Results Survey in Patients With Hyperactivity, or Aggressive Behavior Associated With Alzheimer's Dementia
- Where
- Osaka
- Életkor
- 15 év and over
- People
- 200
- Run by
- Otsuka Pharmaceutical Co., Ltd.
See details and how to joinNCT06875986 - 2. fázisTaking peopleA Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
- Where
- Chiba, Fukuoka, Hirakata, Kanzaki-gun, Kawasaki, Kurashiki, Narashino, Ōbu, Okayama, Shinjuku, Tsu
- Életkor
- 50 év to 85 év
- People
- 340 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07033494 · EU 2024-519190-19-00 - 3. fázisTaking peopleScreening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
- Where
- Aichi, Hiroshima, Hyōgo, Kagawa, Kanagawa, Kochi, Kyoto, Meguro-Ku, Mie, Okayama, Osaka, Tokyo, Yamagata
- Életkor
- 50 év to 90 év
- People
- 80 000 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07177352 - 3. fázisTaking peopleOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
- Where
- Hachiōji, Hadano, Himeji-Shi, Hiroshima, Iizuka, Kawasaki-Shi, Kōriyama, Kumamoto, Kyoto, Sakai, Sapporo, Setagaya-Ku, tabashi City, Takamatsu, Takatsuki, Tatebayashi, Toride-shi, Tsu, Yokohama, Yoshinogawa
- Életkor
- 55 év to 90 év
- People
- 1000 worldwide
- Run by
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT05980949 · EU 2023-504151-27-00 - 3. fázisTaking peopleA Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
- Where
- Bunkyo-ku, Fukuoka, Hadano, Kanzaki-Gun Yoshinogari-Cho, Karatsu-shi, Kawasaki, Okayama, Sakai, Shimotsuke-shi, Tochigi
- Életkor
- 55 év to 90 év
- People
- 650 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06937229 · EU 2024-519994-20-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
- Where
- Hirakata, Hiroshima, Ina, Inage, Kamakura, Kashiwazaki, Kawasaki, Kita-gun, Kurashiki, Kyoto, Matsudo, Osaka, Wako, Yoshinogari-cho, Kanzaki-gun
- Életkor
- 60 év to 85 év
- People
- 586 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06976203 · EU 2025-520747-32-00 - 1. fázisNot yet taking people in JapánA Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)
- Where
- Bunkyō City, Ōbu
- Életkor
- 18 év to 85 év
- People
- 111 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07843459 - No phaseTaking peopleDominantly Inherited Alzheimer Network (DIAN)
- Where
- Niigata, Osaka, Tokyo
- Életkor
- 18 év and over
- People
- 700 worldwide
- Run by
- Washington University School of Medicine
See details and how to joinNCT00869817 - 2. fázisTaking peopleA Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia
- Where
- Aichi, Akita, Aomori, Fukui, Fukuoka, Gunma, Hiroshima, Hokkaido, Kagoshima, Kanagawa, Kochi, Kyoto, Miyagi, Nagano, Nara, Osaka, Saga, Saitama, Tokyo, Yamagata
- Életkor
- 55 év to 90 év
- People
- 90
- Run by
- Ono Pharmaceutical Co., Ltd.
See details and how to joinNCT06803823 - 3. fázisTaking peopleEpidemiology and Biomarker Study in Alzheimer's Disease
- Where
- Bunkyō City, Tokyo
- Életkor
- 55 év to 75 év
- People
- 3400 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07142954 - 3. fázisTaking peopleA Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
- Where
- Nankoku-shi, Osaka, Suita
- Életkor
- 55 év to 90 év
- People
- 325 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06947941 - 1. fázisTaking peopleA Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
- Where
- Bunkyō City, Ōbu
- Életkor
- 45 év to 85 év
- People
- 128 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06657768 - No phaseTaking peopleA Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab
- Where
- Hiroshima, Kyoto, Tokyo
- Életkor
- 18 év and over
- People
- 5000
- Run by
- Eisai Co., Ltd.
See details and how to joinNCT06322667